Deciphering unique and shared interactions between the human gut microbiota and oral antidiabetic drugs.

Ren, Huahui; Shi, Zhun; Yang, Fangming; Wang, Shujie; Yuan, Fengyi; Li, Tingting; Li, Min; Zhu, Jiahui; Li, Junhua; Wu, Kui; Zhang, Yifei; Ning, Guang; Kristiansen, Karsten; Wang, Weiqing; Gu, Yanyun; Zhong, Huanzi

Ren, Huahui; Shi, Zhun; Yang, Fangming; Wang, Shujie; Yuan, Fengyi; Li, Tingting; Li, Min; Zhu, Jiahui; Li, Junhua; Wu, Kui; Zhang, Yifei; Ning, Guang; Kristiansen, Karsten; Wang, Weiqing; Gu, Yanyun; Zhong, Huanzi.

Afiliación

Ren H; BGI Research Shenzhen China.
Shi Z; Department of Biology Laboratory of Genomics and Molecular Biomedicine University of Copenhagen Copenhagen Denmark.
Yang F; BGI Research Shenzhen China.
Wang S; BGI Research Shenzhen China.
Yuan F; Department of Endocrine and Metabolic Diseases Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China.
Li T; Shanghai National Clinical Research Center for Metabolic Diseases Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai Chin
Li M; Department of Endocrinology and Metabolism Shenzhen People's Hospital Shenzhen China.
Zhu J; Department of Endocrine and Metabolic Diseases Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China.
Li J; Shanghai National Clinical Research Center for Metabolic Diseases Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai Chin
Wu K; BGI Research Shenzhen China.
Zhang Y; BGI Research Shenzhen China.
Ning G; BGI Research Shenzhen China.
Kristiansen K; Shenzhen Key Laboratory of Unknown Pathogen Identification, BGI Research Shenzhen China.
Wang W; BGI Research Shenzhen China.
Gu Y; Guangdong Provincial Key Laboratory of Human Disease Genomics, Shenzhen Key Laboratory of Genomics, BGI Research Shenzhen China.
Zhong H; Department of Endocrine and Metabolic Diseases Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China.

Imeta ; 3(2): e179, 2024 Apr.

Article en En | MEDLINE | ID: mdl-38882498

ABSTRACT

ABSTRACT

The administration of oral antidiabetic drugs (OADs) to patients with type 2 diabetes elicits distinct and shared changes in the gut microbiota, with acarbose and berberine exhibiting greater impacts on the gut microbiota than metformin, vildagliptin, and glipizide. The baseline gut microbiota strongly associates with treatment responses of OADs.

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Imeta Año: 2024 Tipo del documento: Article